alendronate has been researched along with Disease Exacerbation in 36 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin." | 9.19 | Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014) |
| "The study aimed to investigate the effect of alendronate (ALN) on the inhibition of alveolar bone loss in experimental periodontitis in Wistar rats." | 7.83 | Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats. ( Crivellaro, V; Deliberador, TM; Giovanini, AF; Romito, GA; Storrer, CLM; Zielak, JC, 2016) |
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 7.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| "Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling." | 5.40 | Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. ( de Blois, E; de Jong, M; Groen, HC; Koelewijn, SJ; Müller, C; Siebelt, M; Verhaar, JA; Waarsing, JH; Weinans, H, 2014) |
| "Alendronate (ALN) can increase bone mass and improve the microstructure of osteoporotic vertebrae, which might be helpful in preserving disc morphology and mechanical properties." | 5.39 | Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. ( Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ, 2013) |
| "A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin." | 5.19 | Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014) |
| "We conducted a retrospective study in our facility for comparing the pharmacological effects of teriparatide and alendronate on 32 NOFH patients diagnosed with osteoporosis." | 3.85 | Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate. ( Arai, R; Asano, T; Inoue, M; Irie, T; Iwasaki, N; Kondo, E; Konno, T; Onodera, T; Takahashi, D; Terkawi, MA, 2017) |
| "The study aimed to investigate the effect of alendronate (ALN) on the inhibition of alveolar bone loss in experimental periodontitis in Wistar rats." | 3.83 | Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats. ( Crivellaro, V; Deliberador, TM; Giovanini, AF; Romito, GA; Storrer, CLM; Zielak, JC, 2016) |
| "To investigate the disease modifying effects of cathepsin K (CatK) inhibitor L-006235 compared to alendronate (ALN) in two preclinical models of osteoarthritis (OA)." | 3.78 | Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. ( Duong, LT; Hayami, T; Pickarski, M; Wesolowski, GA; Zhuo, Y, 2012) |
| "No BMD test or alendronate therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or universal alendronate therapy without a BMD test." | 3.76 | Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. ( Elkin, EB; Girotra, M; Ito, K; Morris, MJ, 2010) |
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 3.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| "Alendronate treatment by standard dose for osteoporosis showed clinical efficacy for decreasing pain but failed to show preventive effects for structural progression of hip osteoarthritis." | 2.78 | Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. ( Nishii, T; Shiomi, T; Sugano, N; Tamura, S; Yoshikawa, H, 2013) |
| "Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling." | 1.40 | Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. ( de Blois, E; de Jong, M; Groen, HC; Koelewijn, SJ; Müller, C; Siebelt, M; Verhaar, JA; Waarsing, JH; Weinans, H, 2014) |
| "Alendronate (ALN) can increase bone mass and improve the microstructure of osteoporotic vertebrae, which might be helpful in preserving disc morphology and mechanical properties." | 1.39 | Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. ( Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ, 2013) |
| "There are very few cases of pathological fracture induced by pancreatitis that affect the vertebrae." | 1.37 | Pathological fracture due to vertebral osteonecrosis associated with pancreatitis. ( Baba, T; Kaneko, H; Shitoto, K; Yoshioka, C, 2011) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| "We established an in vivo ovarian cancer model with i." | 1.33 | Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. ( Hashimoto, K; Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Tahara, M; Tasaka, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (38.89) | 29.6817 |
| 2010's | 21 (58.33) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Pawade, TA | 1 |
| Doris, MK | 1 |
| Bing, R | 1 |
| White, AC | 1 |
| Forsyth, L | 1 |
| Evans, E | 1 |
| Graham, C | 1 |
| Williams, MC | 1 |
| van Beek, EJR | 1 |
| Fletcher, A | 1 |
| Adamson, PD | 1 |
| Andrews, JPM | 1 |
| Cartlidge, TRG | 1 |
| Jenkins, WSA | 1 |
| Syed, M | 1 |
| Fujisawa, T | 1 |
| Lucatelli, C | 1 |
| Fraser, W | 1 |
| Ralston, SH | 1 |
| Boon, N | 1 |
| Prendergast, B | 1 |
| Newby, DE | 1 |
| Dweck, MR | 1 |
| Campbell, GM | 1 |
| Tower, RJ | 1 |
| Damm, T | 1 |
| Kneissl, P | 1 |
| Rambow, AC | 1 |
| Schem, C | 1 |
| Tiwari, S | 1 |
| Glüer, CC | 1 |
| Luo, Y | 1 |
| Zhang, L | 1 |
| Wang, WY | 1 |
| Hu, QF | 1 |
| Song, HP | 1 |
| Su, YL | 1 |
| Zhang, YZ | 1 |
| Jensen, TW | 1 |
| Hansen, MS | 1 |
| Hørslev-Petersen, K | 1 |
| Hyldstrup, L | 1 |
| Abrahamsen, B | 1 |
| Langdahl, B | 1 |
| Zerahn, B | 1 |
| Pødenphant, J | 1 |
| Stengaard-Petersen, K | 1 |
| Junker, P | 1 |
| Østergaard, M | 1 |
| Lottenburger, T | 1 |
| Ellingsen, T | 1 |
| Andersen, LS | 1 |
| Hansen, I | 1 |
| Skjødt, H | 1 |
| Pedersen, JK | 1 |
| Lauridsen, UB | 1 |
| Svendsen, AJ | 1 |
| Tarp, U | 1 |
| Lindegaard, H | 1 |
| Jurik, AG | 1 |
| Vestergaard, A | 1 |
| Hetland, ML | 1 |
| Nishii, T | 2 |
| Tamura, S | 1 |
| Shiomi, T | 1 |
| Yoshikawa, H | 2 |
| Sugano, N | 2 |
| Lai, WS | 1 |
| Lee, JC | 1 |
| Vaishya, R | 1 |
| Vijay, V | 1 |
| Vaish, A | 1 |
| Siebelt, M | 1 |
| Waarsing, JH | 1 |
| Groen, HC | 1 |
| Müller, C | 1 |
| Koelewijn, SJ | 1 |
| de Blois, E | 1 |
| Verhaar, JA | 1 |
| de Jong, M | 1 |
| Weinans, H | 1 |
| Duarte, JH | 1 |
| Moreira, MM | 1 |
| Bradaschia-Correa, V | 1 |
| Marques, ND | 1 |
| Ferreira, LB | 1 |
| Arana-Chavez, VE | 1 |
| Stuckey, BG | 1 |
| Sallie, R | 1 |
| Storrer, CLM | 1 |
| Deliberador, TM | 1 |
| Giovanini, AF | 1 |
| Crivellaro, V | 1 |
| Zielak, JC | 1 |
| Romito, GA | 1 |
| Saini, I | 1 |
| Kalaivani, M | 1 |
| Kabra, SK | 1 |
| Arai, R | 1 |
| Takahashi, D | 1 |
| Inoue, M | 1 |
| Irie, T | 1 |
| Asano, T | 1 |
| Konno, T | 1 |
| Terkawi, MA | 1 |
| Onodera, T | 1 |
| Kondo, E | 1 |
| Iwasaki, N | 1 |
| Lakhotia, SM | 1 |
| Farag, N | 1 |
| Delbanco, T | 1 |
| Strewler, GJ | 1 |
| Lewiecki, EM | 1 |
| Nagayoshi, Y | 1 |
| Kawano, H | 1 |
| Sugiyama, S | 1 |
| Kuroda, Y | 1 |
| Ogawa, H | 1 |
| Baba, T | 1 |
| Shitoto, K | 1 |
| Yoshioka, C | 1 |
| Kaneko, H | 1 |
| Ito, K | 1 |
| Elkin, EB | 1 |
| Girotra, M | 1 |
| Morris, MJ | 1 |
| Hingston, CD | 1 |
| Saayman, AG | 1 |
| Frost, PJ | 1 |
| Wise, MP | 1 |
| Sterbakova, G | 1 |
| Vyskocil, V | 1 |
| Linhartova, K | 1 |
| Agarwala, S | 1 |
| Shah, SB | 1 |
| Kang, P | 1 |
| Pei, F | 1 |
| Shen, B | 1 |
| Zhou, Z | 1 |
| Yang, J | 1 |
| Hayami, T | 2 |
| Zhuo, Y | 1 |
| Wesolowski, GA | 2 |
| Pickarski, M | 2 |
| Duong, LT | 2 |
| Torregrosa, JV | 1 |
| Durán, CE | 1 |
| Barros, X | 1 |
| Blasco, M | 1 |
| Arias, M | 1 |
| Cases, A | 1 |
| Campistol, JM | 1 |
| Hill, JA | 1 |
| Goldin, JG | 1 |
| Gjertson, D | 1 |
| Emerick, AM | 1 |
| Greaser, LD | 1 |
| Yoon, HC | 1 |
| Khorrami, S | 1 |
| Aziz, D | 1 |
| Adams, JS | 1 |
| McLane, J | 1 |
| Bone, A | 1 |
| Destefano, J | 1 |
| Rodan, GA | 1 |
| Hashimoto, K | 1 |
| Morishige, K | 1 |
| Sawada, K | 1 |
| Tahara, M | 1 |
| Kawagishi, R | 1 |
| Ikebuchi, Y | 1 |
| Sakata, M | 1 |
| Tasaka, K | 1 |
| Murata, Y | 1 |
| Desai, MM | 1 |
| Sonone, S | 1 |
| Bhasme, V | 1 |
| Lai, KA | 1 |
| Shen, WJ | 1 |
| Yang, CY | 1 |
| Shao, CJ | 1 |
| Hsu, JT | 1 |
| Lin, RM | 1 |
| Miki, H | 1 |
| Hashimoto, J | 1 |
| Wang, CJ | 1 |
| Wang, FS | 1 |
| Yang, KD | 1 |
| Huang, CC | 1 |
| Lee, MS | 1 |
| Chan, YS | 1 |
| Wang, JW | 1 |
| Ko, JY | 1 |
| Ding, M | 1 |
| Danielsen, CC | 1 |
| Hvid, I | 1 |
| Neogi, T | 1 |
| Nevitt, MC | 1 |
| Ensrud, KE | 1 |
| Bauer, D | 1 |
| Felson, DT | 1 |
| Yee, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis[NCT02132026] | Phase 2 | 152 participants (Actual) | Interventional | 2014-11-12 | Completed | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis[NCT00265252] | Phase 4 | 60 participants | Interventional | 2005-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Disease Exacerbation
| Article | Year |
|---|---|
Denosumab update.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone | 2009 |
8 trials available for alendronate and Disease Exacerbation
| Article | Year |
|---|---|
Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Denos | 2021 |
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Topics: Adult; Aged; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density; | 2014 |
Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone | 2013 |
Are the results of multiple drilling and alendronate for osteonecrosis of the femoral head better than those of multiple drilling? A pilot study.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Combined Modality Therapy; Decompression, Surg | 2012 |
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphon | 2012 |
The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.
Topics: Adult; Aged; Alendronate; Bone Diseases; Diphosphonates; Disease Progression; Female; Femur Head Nec | 2005 |
Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate.
Topics: Administration, Oral; Adolescent; Adult; Alendronate; Bone Density Conservation Agents; Combined Mod | 2008 |
The effect of alendronate on progression of spinal osteophytes and disc-space narrowing.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Disease Progression; Female; Humans; Interverte | 2008 |
27 other studies available for alendronate and Disease Exacerbation
| Article | Year |
|---|---|
Tracking the Progression of Osteolytic and Osteosclerotic Lesions in Mice Using Serial In Vivo μCT: Applications to the Assessment of Bisphosphonate Treatment Efficacy.
Topics: Alendronate; Animals; Bone Resorption; Cell Line, Tumor; Diphosphonates; Disease Progression; Female | 2018 |
Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Co | 2013 |
Fibrous dysplasia of the craniofacial bones.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Disease Progression; Facial Asymmetry; Facial B | 2013 |
Spontaneous osteonecrosis of the knee: an unusual cause of knee pain.
Topics: Acute Disease; Adult; Alendronate; Arthralgia; Diclofenac; Disease Progression; Humans; Knee Joint; | 2014 |
Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Bone Resorption; Cartilage, Articular; Disease Pr | 2014 |
Osteoarthritis: alendronate treatment improves pathology in animal model of OA by blocking osteoclastic bone resorption.
Topics: Alendronate; Animals; Bone Resorption; Disease Progression; Male; Osteoarthritis; Osteoclasts | 2014 |
Ultrastructural and immunohistochemical study of the effect of sodium alendronate in the progression of experimental periodontitis in rats.
Topics: Alendronate; Alveolar Process; Animals; Dental Papilla; Disease Progression; Gingiva; Male; Microsco | 2014 |
Alendronate-induced unmasking or deterioration of coeliac disease: a case series.
Topics: Alendronate; Bone Density Conservation Agents; Celiac Disease; Disease Progression; Female; Humans; | 2015 |
Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Disease Progression; Fusobacterium nucleatum; Male; Period | 2016 |
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
Topics: Age of Onset; Alendronate; Calcinosis; Child; Child, Preschool; Delayed Diagnosis; Dermatomyositis; | 2016 |
Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Disease Progression; Drug Eva | 2017 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
Update: A 64-year-old woman with primary hyperparathyroidism.
Topics: Adenoma; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Progressio | 2008 |
A woman with progressive thinning of the skull.
Topics: Aged; Alendronate; Bone Density; Bone Resorption; Disease Progression; Female; Humans; Parietal Bone | 2009 |
Pathological fracture due to vertebral osteonecrosis associated with pancreatitis.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Disease Progression; Fat Necrosis; Fr | 2011 |
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Antineoplastic Agents; Bone Density; Bon | 2010 |
Boerhaave's syndrome - rapidly evolving pleural effusion; a radiographic clue.
Topics: Abdominal Pain; Aged, 80 and over; Alendronate; Biliary Tract Diseases; Bone Density Conservation Ag | 2010 |
Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.
Topics: Aged; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Comorbidity; | 2010 |
Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Disease Progression; Female; Femur Head Necros | 2011 |
Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis.
Topics: Alendronate; Animals; Anterior Cruciate Ligament Injuries; Benzamides; Biomarkers; Bone Density Cons | 2012 |
Progression of coronary artery calcification in patients taking alendronate for osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Calcinosis; Cal | 2002 |
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
Topics: Acid Phosphatase; Alendronate; Animals; Anterior Cruciate Ligament; Bone Remodeling; Calcinosis; Car | 2004 |
Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Topics: Alendronate; Animals; CA-125 Antigen; Cell Line, Tumor; Disease Progression; Female; Mice; Mice, Inb | 2005 |
Efficacy of alendronate in the treatment of avascular necrosis of the hip.
Topics: Alendronate; Disease Progression; Femur Head Necrosis; Humans; Magnetic Resonance Imaging; Treatment | 2005 |
Does alendronate prevent collapse in osteonecrosis of the femoral head?
Topics: Adolescent; Adult; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Ag | 2006 |
The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodelin | 2008 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |